Figure 3 Strategies to improve liver regeneration

Slides:

Advertisements

Similar presentations

What exactly is it that we are responsible for knowing from this website? There are many different photos of many different specific types of tumors...which.

Advertisements

Figure 1 Proposed risk stratification for patients with NAFLD

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Figure 3 Extracellular stimuli to HSC activation

Figure 1 Contribution of the gut microbiota

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Figure 7 Treatment algorithm for perianal fistulizing disease

Figure 6 Injection of mesenchymal stem cells in perianal fistulas

Figure 7 Management algorithm for patients with ACLF

Figure 5 Lipid droplet consumption

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Figure 2 The microbiome–gut–brain axis

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Figure 1 Immune mechanisms in liver homeostasis

Figure 2 Signalling molecules and pathways involved in HSC activation

Figure 1 Biosimilar development process

Figure 2 The concept of the hepatic reserve and ACLF

Figure 4 Giant lipid droplet formation

Figure 4 Tumour-induced neutrophil extracellular trap

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Figure 6 Combination therapy for HCC

Figure 2 Modelling the effect of HCV treatment on reinfection in people who inject drugs Figure 2 | Modelling the effect of HCV treatment on reinfection.

Figure 4 Proinflammatory immune cells and their crosstalk in patients with IBD Figure 4 | Proinflammatory immune cells and their crosstalk in patients.

Figure 1 Definition and concept of ACLF

Figure 1 Functions, features and phenotypes of HSCs in normal and diseased livers Figure 1 | Functions, features and phenotypes of HSCs in normal and diseased.

Figure 2 Switching of biologic agents and biosimilars

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Senescence: Not Just for Tumor Suppression

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Mechanisms of Hepatic Fibrogenesis

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Mesenchymal stromal cell therapy for liver diseases

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

to the liver and promote patient-derived xenograft tumour growth

different types of liver cells

Figure 4 Histological pattern in ACLF

Figure 3 Clinical algorithms in the management of NASH and diabetes mellitus Figure 3 | Clinical algorithms in the management of NASH and diabetes mellitus.

Figure 5 Hepatic regeneration in ACLF

Figure 2 13C-octanoic acid gastric emptying breath test

in the UK (1961–2012), France (1961–2014) and Italy (1961–2010)

Figure 5 Chrononutrition in the liver

Figure 2 Key brain–immune–gut interactions

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Figure 4 Towards more physiologically relevant 2D

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Figure 6 Possible therapeutic targets to decrease hepatic steatosis

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Figure 2 Schematic of normal and abnormal liver regeneration

Nitin Raj, Laura D. Attardi Current Biology

Figure 1 Animal models of liver regeneration

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Volume 146, Issue 5, Pages (May 2014)

Figure 7 T cells in liver inflammation

Figure 6 Innate lymphoid cells in liver inflammation

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Figure 2 New therapeutic approaches in IBD with their specific targets

Figure 4 Role of exosomes in the pathogenesis of alcoholic hepatitis

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Diarmaid Dominic Houlihan, Philip Noel Newsome Gastroenterology

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Figure 1 NAFLD pathogenesis

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

The balance between Notch/Wnt signaling regulates progenitor cells’ commitment during liver repair: Mystery solved? Mario Strazzabosco, Luca Fabris

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Figure 1 The spread of colorectal cancer metastases

Presentation transcript:

Figure 3 Strategies to improve liver regeneration Figure 3 | Strategies to improve liver regeneration. Strategies to improve liver regeneration include the removal of injurious agents, the promotion of fibrosis resolution and the direct stimulation of hepatocyte proliferation. The balance between these two sets of processes is key in determining the clinical outcome. GCSF, granulocyte colony-stimulating factor; HSC, hepatic stellate cell; MSC, mesenchymal stromal cell; T3, thyroid hormone. Forbes, S. J. & Newsome, P. N. (2016) Liver regeneration — mechanisms and models to clinical application Nat. Rev. Gastroenterol. Hepatol. doi:10.1038/nrgastro.2016.97